“Cost‑effectiveness Analysis of Apixaban Versus Other NOACs for the Prevention of Stroke in Italian Atrial Fibrillation Patients”. 2014. Farmeconomia. Health Economics and Therapeutic Pathways 15 (4): 101-12. https://doi.org/10.7175/fe.v15i4.971.